Drug Master File (DMF) is a document prepared by
a pharmaceutical manufacturer and submitted solely at its discretion
to the appropriate regulatory authority in the intended drug market. There is
no regulatory requirement to file a DMF.
However, the document provides the regulatory
authority with confidential, detailed information about facilities, processes,
or articles used in the manufacturing, processing, packaging, and storing of
one or more human drugs.
Typically, a DMF is filed when two or more firms
work in partnership on developing or manufacturing a drug product.
The DMF filing allows a firm to protect its intellectual
property from its partner while complying with regulatory requirements for
disclosure of processing details.
What does the DMF
contains?
Drug Master File (DMF) is a document containing
complete information on an Active Pharmaceutical Ingredient (API) or
finished drug dosage form.
It is known as European Drug Master File (EDMF) or
Active Substance Master File (ASMF) and US-Drug Master file (US-DMF) in Europe
and United States respectively.
The DMF contains factual and complete information
on a drug product's chemistry, manufacture, stability, purity, impurity
profile, packaging, and the cGMP status of any human drug product.
DMFs in the United States
In the
United States, DMFs are submitted to the Food and Drug
Administration (FDA). The Main Objective of the DMF is to support
regulatory requirements and to prove the quality, safety and efficacy of the
medicinal product for obtaining an Investigational New Drug Application
(IND), a New Drug Application (NDA), an Abbreviated New Drug
Application (ANDA), another DMF, or an Export Application.
In United States there are 5 types of Drug Master File:
·
Type I
Manufacturing Site, Facilities, Operating Procedures, and Personnel
·
Type II
Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation,
or Drug Product
·
Type III
Packaging Material
·
Type IV
Excipient, Colorant, Flavor, Essence, or Material Used in Their Preparation
·
Type V
FDA Accepted Reference Information
DMFs in Europe
The content and the format for drug master file
used in United States differ from that used in European Countries to obtain
market authorization (MA).
The Main Objective of the EDMF is to support
regulatory requirements of a medicinal product to prove its quality, safety and
efficacy. This helps to obtain a Marketing Authorization grant.
No comments:
Post a Comment